Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas

The POLARIX trial demonstrated the superiority of polatuzumab vedotin (Pola) over vincristine in the rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) regimen for large B-cell lymphomas, but it is unknown whether Pola can be safely incorporated into intensified regimens (eg, dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynch, Ryan C., Poh, Christina, Ujjani, Chaitra S., Warren, Edus H., Smith, Stephen D., Shadman, Mazyar, Morris, Karolyn, Lee, Sydney, Rasmussen, Heather, Ottemiller, Susan, Shelby, Megan, Keo, Sarith, Verni, Kaitlin, Kurtz, David M., Alizadeh, Ash A., Chabon, Jacob J., Hogan, Gregory J., Schulz, Andre, Gooley, Ted, Voutsinas, Jenna M., Gopal, Ajay K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241852/
https://www.ncbi.nlm.nih.gov/pubmed/36521030
http://dx.doi.org/10.1182/bloodadvances.2022009145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241852/
https://www.ncbi.nlm.nih.gov/pubmed/36521030
http://dx.doi.org/10.1182/bloodadvances.2022009145

Ejemplares similares